Drugs / Sulfur Hexafluoride Microspheres
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03652636 | Aug 2019 → Jul 2023 | liver disorder | Indiana University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulfur Hexafluoride Microspheres | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03652636 ↗ |
| Known as | sulfur hexafluoride lipid-type A microspheres | “Sonographic images obtained before and after intravenous administration of 2 mL sulfur hexafluoride lipid-type A microspheres (Lumason) per lesion totaling 59 lesions (27 FNHs/32 HCAs).” PMID 39589314 ↗ Nov 2024 |
| Route | Intravenous | “2.5 mL intravenous injection given at the time of ultrasound” NCT03652636 ↗ |